Q4 2024 Earnings Call Transcript March 20, 2025 Monte Rosa Therapeutics, Inc. beats earnings expectations. Reported EPS is $0 ...
The Artisan International Small-Mid Fund portfolio outperformed the MSCI ACWI ex USA SMID Index in Q4 of 2024. Click here to ...
The following is a summary of “Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” ...
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with a rapidly increasing global prevalence. It is primarily ...
Ongoing TX45 APEX Phase 2 Clinical Trial Results Expected in 2026: The global, 24-week APEX Phase 2 clinical trial is a double-blind, randomized, placebo-controlled study designed to evaluate the ...
Addiction and obesity share deep neurological roots. Can new treatments like GLP-1 drugs and MEAI help break the cycle?
BRP, identified through peptide prediction, may revolutionize weight loss treatment, offering efficacy without the ...
AZoLifeSciences on MSN5d
Stanford Researchers Find a Molecule That Rivals Ozempic in Weight LossBRP emerges as a promising peptide for weight loss, activating appetite control pathways without triggering nausea, paving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback